AffaMed Therapeutics (AffaMed), a global clinical stage biopharmaceutical company, announced the appointment of Vijay Karwal as Chief Financial Officer. Reporting to AffaMed’s CEO Dr. Dayao Zhao, Karwal will be responsible for all aspects of financial management and will work closely with AffaMed’s leadership team to support the company’s advancement into a leading biopharmaceuticals company. “We are extremely pleased…